Background: To determine the diagnostic accuracy of a rapid heart-type fatty acid-binding protein (H-FABP) test in patients suspected of acute coronary syndrome (ACS) in primary care.

Methods: General practitioners included 298 patients suspected of ACS. In all patients, whether referred to hospital or not, ECG and cardiac biomarker testing was performed. ACS was determined in accordance with international guidelines. Multivariate analysis was used to determine the value of H-FABP in addition to clinical findings.

Results: Mean patient age was 66 years (SD 14), 52% was female and 66 patients (22%) were diagnosed with ACS. The H-FABP bedside test was performed within 24h (median 3.1, IQR 1.5 to 7.1) after symptom onset. The positive predictive value (PPV) of H-FABP was 65% (95% confidence interval (CI) 50-78). The negative predictive value (NPV) was 85% (95% CI 80-88). Sensitivity was 39% (29-51%) and specificity 94% (90-96%). Within 6h after symptom onset, the PPV was 72% (55-84) and the NPV was 83% (77-88), sensitivity 43% (31-57%) and specificity 94% (89-97%). Adding the H-FABP test to a diagnostic model for ACS led to an increase in the area under the receiver operating curve from 0.66 (95% CI 0.58-0.73) to 0.75 (95% CI 0.68-0.82).

Conclusion: The H-FABP rapid test provides modest additional diagnostic certainty in primary care. It cannot be used to safely exclude rule out ACS. The test can only be used safely in patients otherwise NOT referred to hospital by the GP, as an extra precaution not to miss ACS ('rule in').

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijcard.2012.12.050DOI Listing

Publication Analysis

Top Keywords

heart-type fatty
8
fatty acid-binding
8
acid-binding protein
8
protein h-fabp
8
h-fabp bedside
8
bedside test
8
suspected acute
8
acute coronary
8
coronary syndrome
8
primary care
8

Similar Publications

Introduction: For patients with breast cancer receiving preoperative neoadjuvant chemotherapy with anthracyclines, there is an increased risk of postoperative myocardial injury due to the cardiotoxicity of the chemotherapeutic agents. The optimal intraoperative blood pressure regulation regimen for these patients is unclear. This study is being conducted to determine whether targeting mean arterial pressure (MAP) to 100%-120% of the patient's baseline blood pressure reduces the incidence of myocardial injury after non-cardiac surgery (MINS) compared with targeting MAP to 80%-100%.

View Article and Find Full Text PDF

An electrochemiluminescence biosensor based on silver-cysteine nanorod as an emitter and AgNP-decorated FeMoO as a signal amplifier for sensitive detection of heart-type fatty acid binding protein.

Mikrochim Acta

December 2024

State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Collaborative Innovation Center for Guangxi Ethnic Medicine, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin, 541004, China.

An electrochemiluminescence (ECL) immunosensor was developed for the highly sensitive and specific detection of heart-type fatty acid binding protein (H-FABP) and the rapid diagnosis of acute myocardial infarction (AMI). H-FABP is a biomarker that is highly specific to cardiac tissue and is associated with a range of cardiac diseases. Following myocardial injury, the rate of increase in H-FABP levels is greater than that observed for myoglobin and troponin.

View Article and Find Full Text PDF

Novel Biomarkers as Potential Predictors of Decompensated Advanced Chronic Heart Failure-Single Center Study.

J Clin Med

November 2024

Department for Cardiology I, Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital Münster, 48149 Münster, Germany.

Heart failure (HF) remains a major therapeutic and diagnostic challenge nowadays. Albeit, acute decompensated HF is associated with several clinical signs such as dyspnea or edema, it remains a challenge to use easy accessible and suitable tools, such as biomarkers, to distinguish between patients at risk for an acute decompensation of their heart failure and compensated, stable HF patients. Existing biomarkers, such as natriuretic peptides or troponin, are not specific and can be elevated due to several other disease conditions, such as myocardial infarction, atrial fibrillation, or valve diseases.

View Article and Find Full Text PDF

Aim: In 2019, cardiovascular diseases accounted for 32% of global deaths. So, early detection of cardiac disorders is crucial. The study aimed to examine the suitability of Pro-neurotensin and Heart-type fatty acid binding protein as dependable biomarkers for cardiac patients with Heart failure as a primary diagnosis.

View Article and Find Full Text PDF

Management of Acute Pulmonary Embolism: A Review.

J Assoc Physicians India

November 2024

Consultant and Head, Department of Cardiology, Safdarjung Hospital, Delhi, India.

Article Synopsis
  • Pulmonary embolism (PE) is a significant health concern in India, often missed or poorly managed, leading to increased risk of cardiovascular issues in hospitalized patients.
  • Current research and studies have improved understanding of PE diagnosis, assessment, and treatment strategies, emphasizing the need for risk stratification of patients based on mortality risk.
  • Recommended treatments include the use of anticoagulants and thrombolytics, with oral anticoagulants like warfarin and newer options (NOACs) being preferred for their ease of use and effectiveness at the time of diagnosis.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!